Head and Neck Atopic Dermatitis: Therapeutic Response After Switching to Upadacitinib in Moderate-to-Severe Atopic Dermatitis Patients Who Had Inadequate Response to Dupilumab. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 10, n. 2, p. s740, 2026. DOI: 10.25251/ztj3rn69. Disponível em: https://skin.dermsquared.com/skin/article/view/4098. Acesso em: 2 may. 2026.